CD274 and neoplasm: Regorafenib, a multikinase inhibitor approved for advanced colorectal cancer, hepatocellular carcinoma, and gastrointestinal stromal tumors,8 has demonstrated clinical activity against placebo in advanced STS patients.9–11 Preclinical research suggests that regorafenib exerts immunomodulatory effects by altering immune cell function, regulating PD-L1 and MHC-I expression on tumor cells, and promoting normalization of aberrant tumor vasculature.12